Raphael, D, Brown, I, Renwick, R, Rootman, I. Quality of life: what are the implications for health promotion? American Journal of Health Behavior, 1997;21:118–28.Google Scholar

Ballman, KV, Buckner, JC, Brown, PD, Giannini, C, Flynn, PJ, LaPlant, BR, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro-Oncology, 2007;9(1):29–38.CrossRefGoogle ScholarPubMed

Liu, R, Page, M, Solheim, K, Fox, S, Chang, SM. Quality of life in adults with brain tumors: current knowledge and future directions. Neuro-Oncology, 2009;11(3):330–9.CrossRefGoogle ScholarPubMed

Kiebert, GM, Curran, D, Aaronson, NK. Quality of life as an endpoint in EORTC clinical trials. European Organization for Research and Treatment of Cancer. Statistics in Medicine, 1998;17(5–7):561–9.3.0.CO;2-S>CrossRefGoogle Scholar

Cella, DF, Tulsky, DS, Gray, G, Sarafian, B, Linn, E, Bonomi, A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. Journal of Clinical Oncology, 1993;11(3):570–9.CrossRefGoogle ScholarPubMed

Taphoorn, MJ, Stupp, R, Coens, C, Osoba, D, Kortmann, R, van den Bent, MJ, et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. The Lancet Oncology, 2005;6(12):937–44.CrossRefGoogle ScholarPubMed

Aaronson, NK, Taphoorn, MJ, Heimans, JJ, Postma, TJ, Gundy, CM, Beute, GN, et al. Compromised health-related quality of life in patients with low-grade glioma. Journal of Clinical Oncology, 2011;29(33):4430–5.CrossRefGoogle ScholarPubMed

Giovagnoli, AR, Silvani, A, Colombo, E, Boiardi, A. Facets and determinants of quality of life in patients with recurrent high grade glioma. Journal of Neurology, Neurosurgery, and Psychiatry, 2005;76(4):562–8.CrossRefGoogle ScholarPubMed

Renwick, R, Brown, M, Nagler, M. Quality of Life in Health Promotion and Rehabilitation: Conceptual Approaches, Issues and Applications. Thousand Oaks, CA: SAGE Publications; 1996.Google Scholar

Aaronson, NK. Quality of life: what is it? How should it be measured? Oncology, 1988;2(5):64,69–76.Google ScholarPubMed

Weitzner, MA, Meyers, CA, Gelke, CK, Byrne, KS, Cella, DF, Levin, VA. The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer, 1995;75(5):1151–61.3.0.CO;2-Q>CrossRefGoogle ScholarPubMed

Aaronson, NK, Ahmedzai, S, Bergman, B, Bullinger, M, Cull, A, Duez, NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 1993;85(5):365–76.CrossRefGoogle ScholarPubMed

Osoba, D, Aaronson, NK, Muller, M, Sneeuw, K, Hsu, MA, Yung, WK, et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Quality of Life Research, 1996;5(1):139–50.CrossRefGoogle ScholarPubMed

Cleeland, CS, Mendoza, TR, Wang, XS, Chou, C, Harle, MT, Morrissey, M, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer, 2000;89(7):1634–46.3.0.CO;2-V>CrossRefGoogle Scholar

Armstrong, TS, Mendoza, T, Gning, I, Coco, C, Cohen, MZ, Eriksen, L, et al. Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). Journal of Neuro-Oncology, 2006;80(1):27–35.CrossRefGoogle Scholar

Giesinger, JM, Golser, M, Erharter, A, Kemmler, G, Schauer-Maurer, G, Stockhammer, G, et al. Do neurooncological patients and their significant others agree on quality of life ratings? Health and Quality of Life Outcomes, 2009;7:87.CrossRefGoogle ScholarPubMed

Brown, PD, Maurer, MJ, Rummans, TA, Pollock, BE, Ballman, KV, Sloan, JA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery, 2005;57(3):495–504.CrossRefGoogle ScholarPubMed

Mauer, M, Stupp, R, Taphoorn, MJ, Coens, C, Osoba, D, Marosi, C, et al. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. British Journal of Cancer, 2007;97(3):302–7.CrossRefGoogle ScholarPubMed

Budrukkar, A, Jalali, R, Dutta, D, Sarin, R, Devlekar, R, Parab, S, et al. Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice. Journal of Neuro-Oncology, 2009;95(3):413–19.CrossRefGoogle ScholarPubMed

Salo, J, Niemela, A, Joukamaa, M, Koivukangas, J. Effect of brain tumour laterality on patients’ perceived quality of life. Journal of Neurology, Neurosurgery, and Psychiatry, 2002;72(3):373–7.CrossRefGoogle ScholarPubMed

Ruge, MI, Ilmberger, J, Tonn, JC, Kreth, FW. Health-related quality of life and cognitive functioning in adult patients with supratentorial WHO grade II glioma: status prior to therapy. Journal of Neuro-Oncology, 2011;103(1):129–36.CrossRefGoogle ScholarPubMed

Yavas, C, Zorlu, F, Ozyigit, G, Gurkaynak, M, Yavas, G, Yuce, D, et al. Health-related quality of life in high-grade glioma patients: a prospective single-center study. Supportive Care in Cancer, 2012;20(10):2315–25.Google ScholarPubMed

Osoba, D, Brada, M, Prados, MD, Yung, WK. Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro-Oncology, 2000;2(4):221–8.CrossRefGoogle ScholarPubMed

Jakola, AS, Unsgard, G, Myrmel, KS, Kloster, R, Torp, SH, Sagberg, LM, et al. Surgical strategies in low-grade gliomas and implications for long-term quality of life. Journal of Clinical Neuroscience, 2014;21(8):1304–9.CrossRefGoogle ScholarPubMed

Daigle, K, Fortin, D, Mathieu, D, Saint-Pierre, AB, Pare, FM, de la Sablonniere, A, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed patients with glioblastoma: a report on 19 patients surviving to follow-up. Current Medical Research and Opinion, 2013;29(10):1307–13.CrossRefGoogle Scholar

Jakola, AS, Unsgard, G, Solheim, O. Quality of life in patients with intracranial gliomas: the impact of modern image-guided surgery. Journal of Neurosurgery, 2011;114(6):1622–30.CrossRefGoogle ScholarPubMed

Kiebert, GM, Curran, D, Aaronson, NK, Bolla, M, Menten, J, Rutten, EH, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. European Journal of Cancer, 1998;34(12):1902–9.CrossRefGoogle ScholarPubMed

Douw, L, Klein, M, Fagel, SS, van den Heuvel, J, Taphoorn, MJ, Aaronson, NK, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurology, 2009;8(9):810–18.CrossRefGoogle ScholarPubMed

Klein, M. Health-related quality of life aspects in patients with low-grade glioma. Advances and Technical Standards in Neurosurgery, 2010;35:213–35.CrossRefGoogle ScholarPubMed

Struik, K, Klein, M, Heimans, JJ, Gielissen, MF, Bleijenberg, G, Taphoorn, MJ, et al. Fatigue in low-grade glioma. Journal of Neuro-Oncology, 2009;92(1):73–8.CrossRefGoogle ScholarPubMed

Klein, M, Heimans, JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal of Clinical Oncology, 2004;22(5):966–7; author reply 967–8.CrossRefGoogle ScholarPubMed

Klein, M, Engelberts, NH, van der Ploeg, HM, Kasteleijn-Nolst Trenite, DG, Aaronson, NK, Taphoorn, MJ, et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Annals of Neurology, 2003;54(4):514–20.CrossRefGoogle ScholarPubMed

Souhami, L, Seiferheld, W, Brachman, D, Podgorsak, EB, Werner-Wasik, M, Lustig, R, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International Journal of Radiation Oncology, Biology, Physics, 2004;60(3):853–60.CrossRefGoogle ScholarPubMed

Keime-Guibert, F, Chinot, O, Taillandier, L, Cartalat-Carel, S, Frenay, M, Kantor, G, et al. Radiotherapy for glioblastoma in the elderly. New England Journal of Medicine, 2007;356(15):1527–35.CrossRefGoogle ScholarPubMed

Taphoorn, MJ, Bottomley, A. Health-related quality of life and symptom research in glioblastoma multiforme patients. Expert Review of Pharmacoeconomics and Outcomes Research, 2005;5(6):763–74.CrossRefGoogle ScholarPubMed

Osoba, D, Brada, M, Yung, WK, Prados, MD. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. European Journal of Cancer, 2000;36(14):1788–95.CrossRefGoogle ScholarPubMed

Osoba, D, Brada, M, Yung, WK, Prados, M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. Journal of Clinical Oncology, 2000;18(7):1481–91.CrossRefGoogle ScholarPubMed

Taphoorn, MJ, van den Bent, MJ, Mauer, ME, Coens, C, Delattre, JY, Brandes, AA, et al. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. Journal of Clinical Oncology, 2007;25(36):5723–30.CrossRefGoogle ScholarPubMed

Wang, M, Cairncross, G, Shaw, E, Jenkins, R, Scheithauer, B, Brachman, D, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International Journal of Radiation Oncology, Biology, Physics, 2010;77(3):662–9.CrossRefGoogle ScholarPubMed

Chinot, OL, Wick, W, Mason, W, Henriksson, R, Saran, F, Nishikawa, R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. New England Journal of Medicine, 2014;370(8):709–22.CrossRefGoogle ScholarPubMed

Dropcho, EJ, Soong, SJ. Steroid-induced weakness in patients with primary brain tumors. Neurology, 1991;41(8):1235–9.CrossRefGoogle ScholarPubMed

Gilbert, MR, Dignam, JJ, Armstrong, TS, Wefel, JS, Blumenthal, DT, Vogelbaum, MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. New England Journal of Medicine, 2014;370(8):699–708.CrossRefGoogle ScholarPubMed

Vredenburgh, JJ, Cloughesy, T, Samant, M, Prados, M, Wen, PY, Mikkelsen, T, et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. The Oncologist, 2010;15(12):1329–34.CrossRefGoogle ScholarPubMed

Nghiemphu, PL, Liu, W, Lee, Y, Than, T, Graham, C, Lai, A, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology, 2009;72(14):1217–22.CrossRefGoogle ScholarPubMed

Nagpal, S, Harsh, G, Recht, L. Bevacizumab improves quality of life in patients with recurrent glioblastoma. Chemotherapy Research and Practice, 2011;2011:602812.Google ScholarPubMed

Fox, S, Lyon, D, Farace, E. Symptom clusters in patients with high-grade glioma. Oncology Nursing Forum, 2007;34(1):213.Google Scholar

Fox, SW, Lyon, D, Farace, E. Symptom clusters in patients with high-grade glioma. Journal of Nursing Scholarship, 2007;39(1):61–7.CrossRefGoogle ScholarPubMed

Gustafsson, M, Edvardsson, T, Ahlstrom, G. The relationship between function, quality of life and coping in patients with low-grade gliomas. Supportive Care in Cancer, 2006;14(12):1205–12.CrossRefGoogle ScholarPubMed

Osoba, D, Aaronson, NK, Muller, M, Sneeuw, K, Hsu, MA, Yung, WK, et al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. Journal of Neuro-Oncology, 1997;34(3):263–78.CrossRefGoogle ScholarPubMed

Klein, M, Taphoorn, MJ, Heimans, JJ, van der Ploeg, HM, Vandertop, WP, Smit, EF, et al. Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. Journal of Clinical Oncology, 2001;19(20):4037–47.CrossRefGoogle ScholarPubMed

Brown, PD, Ballman, KV, Rummans, TA, Maurer, MJ, Sloan, JA, Boeve, BF, et al. Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. Journal of Neuro-Oncology, 2006;76(3):283–91.CrossRefGoogle ScholarPubMed

Kim, BR, Chun, MH, Han, EY, Kim, DK. Fatigue assessment and rehabilitation outcomes in patients with brain tumors. Supportive Care in Cancer, 2012;20(4):805–12.CrossRefGoogle ScholarPubMed

Lovely, MP, Miaskowski, C, Dodd, M. Relationship between fatigue and quality of life in patients with glioblastoma multiformae. Oncology Nursing Forum, 1999;26(5):921–5.Google ScholarPubMed

Khan, F, Amatya, B. Factors associated with long-term functional outcomes, psychological sequelae and quality of life in persons after primary brain tumour. Journal of Neuro-Oncology, 2013;111(3):355–66.CrossRefGoogle ScholarPubMed

Rooney, AG, Carson, A, Grant, R. Depression in cerebral glioma patients: a systematic review of observational studies. Journal of the National Cancer Institute, 2011;103(1):61–76.CrossRefGoogle ScholarPubMed

Bunevicius, A, Tamasauskas, S, Deltuva, V, Tamasauskas, A, Radziunas, A, Bunevicius, R. Predictors of health-related quality of life in neurosurgical brain tumor patients: focus on patient-centered perspective. Acta Neurochirurgica, 2014;156(2):367–74.CrossRefGoogle ScholarPubMed

Maschio, M, Dinapoli, L. Patients with brain tumor-related epilepsy. Journal of Neuro-Oncology, 2012;109(1):1–6.CrossRefGoogle ScholarPubMed

Maschio, M, Sperati, F, Dinapoli, L, Vidiri, A, Fabi, A, Pace, A, et al. Weight of epilepsy in brain tumor patients. Journal of Neuro-Oncology, 2014;118(2):385–93.CrossRefGoogle ScholarPubMed

Maschio, M, Dinapoli, L, Sperati, F, Fabi, A, Pace, A, Vidiri, A, et al. Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life. Journal of Neuro-Oncology, 2012;106(3):651–6.Google ScholarPubMed

Maschio, M, Dinapoli, L, Sperati, F, Pace, A, Fabi, A, Vidiri, A, et al. Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. Journal of Neuro-Oncology, 2011;104(1):205–14.CrossRefGoogle ScholarPubMed

Maschio, M, Dinapoli, L, Sperati, F, Pace, A, Fabi, A, Vidiri, A, et al. Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. Epileptic Disorders, 2012;14(4):388–97.CrossRefGoogle ScholarPubMed

Meyers, CA, Hess, KR, Yung, WK, Levin, VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. Journal of Clinical Oncology, 2000;18(3):646–50.CrossRefGoogle ScholarPubMed

Rusbridge, SL, Walmsley, NC, Griffiths, SB, Wilford, PA, Rees, JH. Predicting outcomes of vocational rehabilitation in patients with brain tumours. Psycho-Oncology, 2013;22(8):1907–11.CrossRefGoogle ScholarPubMed

Caudill, JS, Brown, PD, Cerhan, JH, Rummans, TA. Selective serotonin reuptake inhibitors, glioblastoma multiforme, and impact on toxicities and overall survival: the Mayo Clinic experience. American Journal of Clinical Oncology-Cancer, 2011;34(4): 385–7.Google ScholarPubMed

Kanter, C, D’Agostino, NM, Daniels, M, Stone, A, Edelstein, K. Together and apart: providing psychosocial support for patients and families living with brain tumors. Supportive Care in Cancer, 2014;22(1):43–52.CrossRefGoogle ScholarPubMed

Quinten, C, Coens, C, Mauer, M, Comte, S, Sprangers, MA, Cleeland, C, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. The Lancet Oncology, 2009;10(9):865–71.CrossRefGoogle ScholarPubMed

Montazeri, A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health and Quality of Life Outcomes, 2009;7:102.CrossRefGoogle ScholarPubMed

Mauer, ME, Taphoorn, MJ, Bottomley, A, Coens, C, Efficace, F, Sanson, M, et al. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. Journal of Clinical Oncology, 2007;25(36):5731–7.CrossRefGoogle ScholarPubMed

Mainio, A, Tuunanen, S, Hakko, H, Niemela, A, Koivukangas, J, Rasanen, P. Decreased quality of life and depression as predictors for shorter survival among patients with low-grade gliomas: a follow-up from 1990 to 2003. European Archives of Psychiatry and Clinical Neuroscience, 2006;256(8):516–21.CrossRefGoogle ScholarPubMed

Gehring, K, Patwardhan, SY, Collins, R, Groves, MD, Etzel, CJ, Meyers, CA, et al. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. Journal of Neuro-Oncology, 2011;107(1):165–74.Google ScholarPubMed

Meyers, CA, Weitzner, MA, Valentine, AD, Levin, VA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. Journal of Clinical Oncology, 1998;16(7):2522–7.CrossRefGoogle ScholarPubMed

Butler, JM, Jr., Case, LD, Atkins, J, Frizzell, B, Sanders, G, Griffin, P, et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. International Journal of Radiation Oncology, Biology, Physics, 2007;69(5):1496–501.CrossRefGoogle ScholarPubMed

Boele, FW, Douw, L, de Groot, M, van Thuijl, HF, Cleijne, W, Heimans, JJ, et al. The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. Neuro-Oncology, 2013;15(10):1420–8.CrossRefGoogle ScholarPubMed

ClinicalTrials.gov. A service of the US National Institutes of Health. Available from: www.clinicaltrials.gov.Google Scholar

Shaw, EG, Rosdhal, R, D’Agostino, RB, Jr., Lovato J, Naughton MJ, Robbins ME, et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. Journal of Clinical Oncology, 2006;24(9):1415–20.CrossRefGoogle Scholar

Attia, A, Rapp, SR, Case, LD, D’Agostino, R, Lesser, G, Naughton, M, et al. Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and mood. Journal of Neuro-Oncology, 2012;109(2):357–63.CrossRefGoogle ScholarPubMed

Gehring, K, Sitskoorn, MM, Gundy, CM, Sikkes, SA, Klein, M, Postma, TJ, et al. Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. Journal of Clinical Oncology, 2009;27(22):3712–22.CrossRefGoogle ScholarPubMed

Locke, DE, Cerhan, JH, Wu, W, Malec, JF, Clark, MM, Rummans, TA, et al. Cognitive rehabilitation and problem-solving to improve quality of life of patients with primary brain tumors: a pilot study. Journal of Supportive Oncology, 2008;6(8):383–91.Google ScholarPubMed

Whiting, DL, Simpson, GK, Koh, ES, Wright, KM, Simpson, T, Firth R. A multi-tiered intervention to address behavioural and cognitive changes after diagnosis of primary brain tumour: a feasibility study. Brain Injury, 2012;26(7–8):950–61.CrossRefGoogle Scholar

Jones, LW, Cohen, RR, Mabe, SK, West, MJ, Desjardins, A, Vredenburgh, JJ, et al. Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing. Journal of Neuro-Oncology, 2009;94(1):79–85.CrossRefGoogle ScholarPubMed